To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective pa...
Do you support it?
Want to know if it passes?
We'll email you when HR 413 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 413.
You're tracking HR 413
We'll email you the moment it moves.
HR 413 — To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Last action — Referred to the Subcommittee on Health.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)
Bill Text
We don't have the full text on file for this bill yet.
Read HR 413 on the official United States source →Action History
-
Referred to the Subcommittee on Health.
-
Referred to the Subcommittee on Health.
-
Referred to House Ways and Means
-
Referred to House Energy and Commerce
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
- Peter Welch · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 413 do?
- Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)
- Who sponsors HR 413?
- HR 413 is sponsored by Peter Welch (D).
- What is the current status of HR 413?
- This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 413?
- Track HR 413 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 413
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 413
Last checked for changes about 8 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →